7075-13-0

Basic information

• Product Name: 1-(5'-O-TRITYL-B-D-ARABINOFURANOSYL) CYT OSINE
• Synonyms: 1-(5'-O-TRITYL-B-D-ARABINOFURANOSYL) CYT OSINE
• CAS NO: 7075-13-0
• Molecular Formula: C₂₈H₂₇N₃O₅
• Molecular Weight: 485.53108
• Mol File: 7075-13-0.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 688.4°C at 760 mmHg
• Flash Point: 370.2°C
• Appearance: /
• Density: 1.33g/cm³
• Vapor Pressure: 6.71E-20mmHg at 25°C
• Refractive Index: 1.658
• CAS DataBase Reference: 1-(5'-O-TRITYL-B-D-ARABINOFURANOSYL) CYT OSINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(5'-O-TRITYL-B-D-ARABINOFURANOSYL) CYT OSINE(7075-13-0)
• EPA Substance Registry System: 1-(5'-O-TRITYL-B-D-ARABINOFURANOSYL) CYT OSINE(7075-13-0)

Safety Data

• Hazardous Substances Data: 7075-13-0(Hazardous Substances Data)

Usage

Chemical structure

A nucleoside analog containing a cytosine base linked to a sugar molecule (B-D-arabinofuranosyl) with a trityl group attached to the sugar molecule.

Antitumor activity

Interferes with DNA replication process in tumor cells, leading to cell death.

Antiviral activity

Shows activity against certain viruses, making it a potential candidate for antiviral therapies.

Synthetic process

The trityl group attached to the sugar molecule protects it during synthesis and can be removed under mild conditions.

Further chemical modifications

The removal of the trityl group exposes the hydroxyl group, allowing for additional chemical modifications.

Research focus

Studies on its potential use in cancer treatment and development of antiviral therapies.

InChI:InChI=1/C28H27N3O5/c29-23-16-17-31(27(34)30-23)26-25(33)24(32)22(36-26)18-35-28(19-10-4-1-5-11-19,20-12-6-2-7-13-20)21-14-8-3-9-15-21/h1-17,22,24-26,32-33H,18H2,(H2,29,30,34)

Upstream product

• 76-83-5 trityl chloride 
• 147-94-4 arabinosyl cytosine 

Downstream Products

• 55726-38-0 N⁴-(4-carboxybutyryl)-1-β-D-arabinofuranosylcytosine 

Relevant articles and documents

Nucleoside drug 5' - position amino acid ester of the regioselective synthesis

The invention relates to a regional selective synthesis method of a nucleoside drug 5'-site amino-acid ester having a structural characteristic as shown in a general formula I and a pharmaceutically acceptable salt thereof, wherein Base, R, R2 and R3 are defined in the specification. The method comprises the steps: utilizing triaryl methyl (Ar3C-) to selectively protect a nucleoside drug 5'-site hydroxy, then utilizing allyloxycarbonyl (AOC) to protect all the rest of active sites in a nucleoside drug base part and a sugar structure part, then selectively removing triaryl methyl under acidity, then carrying out condensation with a Boc-protected amino acid, selectively forming an ester at a 5' site of a nucleoside drug molecule, followed by carrying out palladium catalytic removal of AOC, and finally removing Boc under the acidic condition to form a corresponding salt. The method has high yield, allows the obtained product to be easy to separate and purify, and is more suitable for industrialized production.